Clinical trials
Advanced Breast Cancer clinical trials
Below are recruiting advanced breast cancer clinical trials, each written for real people, not researchers. We’re tracking 937 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07182721RecruitingPhase 2
Study of SKB264 plus Inetetamab for advanced HER2+ breast cancer after T-DXd
This trial is testing a combination of two targeted therapies, SKB264 and Inetetamab, for people with advanced HER2-positive breast cancer that has kept growing after treatment with T-DXd and other HER2-targeted therapies. The goal is to see if this new combination can shrink tumors or slow the cancer's growth.
ShanghaiAges 18 years+ - NCT06889610RecruitingPhase 2
Ablation plus drug therapy for advanced solid tumors
This trial tests combining a liver tumor ablation procedure with systemic drugs for people with advanced colorectal, breast, or melanoma cancer that has spread to the liver. The goal is to see if this approach can help when standard treatments have stopped working.
ShanghaiAges 18–80 - NCT06618287RecruitingPhase 1/Phase 2
Testing BMS-986507 for advanced lung and breast cancers
This study tests a new drug called BMS-986507, given in different combinations, for people with advanced solid tumors (lung cancer or breast cancer that has spread). It looks at safety, how the drug works in the body, and if it helps shrink tumors.
Birmingham, AlabamaAges 18 years+ - NCT05582538RecruitingPhase 2
Ceralasertib plus immunotherapy for advanced triple-negative breast cancer
This Phase 2 trial tests whether a drug called ceralasertib can help the immune system work better, followed by durvalumab plus nab-paclitaxel. It is for people with advanced triple-negative breast cancer whose cancer returned after earlier treatment, including chemotherapy and immune therapy.
Novara, NovaraAges 18 years+ - NCT06495515RecruitingPhase 2
Dalpiciclib plus toremifene for advanced HR+ breast cancer
This trial tests a combination of two drugs (dalpiciclib and toremifene) as a first treatment for advanced breast cancer that is hormone receptor positive and HER2 negative. It may be an option if you have not had hormone therapy for advanced disease or if your cancer came back more than a year after prior treatments.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT06471205RecruitingPhase 2
Study of BL-B01D1 plus immunotherapy for advanced triple-negative breast cancer
This study tests a new drug combination (BL-B01D1 plus an immunotherapy) for people with advanced triple-negative breast cancer who have not had prior treatment for their advanced disease. The goal is to see if the combination works better at shrinking or controlling the cancer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06409390RecruitingPhase 2
Sequential therapy based on tumor evolution for breast cancer
This trial tests a sequence of different treatments for breast cancer that has spread, based on how the cancer evolves. The goal is to find a personalized treatment plan that may work better over time.
Tampa, FloridaAges 18 years+ - NCT06107686RecruitingPhase 2
YL202 for advanced solid tumors
This trial tests a new drug called YL202 for people with advanced solid tumors (cancers that have spread or cannot be removed). It aims to see if the drug can shrink tumors or slow cancer growth. You may be able to join if you have certain types of cancer, have not had a previous HER3 treatment, and can provide a tumor sample.
Hefei, AnhuiAges 18–75 - NCT06067503RecruitingPhase 2
PET scan to detect hormone therapy resistance in breast cancer
This trial tests a new PET scan (called FFNP) to see if it can find which breast cancers stop responding to hormone therapy early. It's for people with advanced hormone-receptor-positive breast cancer who are starting a new endocrine treatment.
Madison, WisconsinAges 18 years+ - NCT05989828RecruitingPhase 1
Engineered immune cells for advanced triple-negative breast cancer
This trial tests a personalized treatment where your own immune cells are modified to recognize and attack cancer cells that have a specific marker called NY-ESO-1. It is for people with triple-negative breast cancer that has not responded to at least two prior treatments.
Los Angeles, CaliforniaAges 18 years+ - NCT05903833RecruitingPhase 2
Study pembrolizumab and lenvatinib for advanced vulvar cancer
This trial tests whether combining pembrolizumab with lenvatinib can shrink and control advanced vulvar squamous cell cancer that can’t be fully treated with surgery or strong radiation. It may help some people live longer and better control symptoms, but it also requires close monitoring and specific health criteria.
AugsburgAges 18 years+ - NCT05800665RecruitingPhase 1
Study tests a new prostate cancer drug after prior hormone therapy
This Phase 1 study tests the safety, how the drug moves through the body, and whether it shows anti-cancer activity in men with advanced or metastatic prostate cancer. It is designed for people whose cancer has already been treated with certain hormone (androgen receptor) therapies.
Scottsdale, ArizonaAges 18 years+ - NCT05696626RecruitingPhase 3
Test a new pill plus abemaciclib versus standard therapy
This Phase 3 study compares lasofoxifene plus abemaciclib versus fulvestrant plus abemaciclib for ER-positive, HER2-negative breast cancer that has an ESR1 mutation. It looks for better tumor control in people whose cancer has progressed on hormone therapy (an aromatase inhibitor) and who meet specific safety and testing requirements.
Scottsdale, ArizonaAges 18 years+ - NCT02102165Recruiting
Study samples from metastatic triple-negative breast cancer
This study looks at tumor “clues” by using tissue and blood samples in people with metastatic breast cancer (with specific subtype). It aims to better understand what drives the cancer, which may help guide future treatments.
BrusselsAges 18 years+ - NCT06663748RecruitingPhase 2
ARX788 for HER2-positive metastatic breast cancer
This trial studies a new drug called ARX788 for people with HER2-positive breast cancer that has spread or cannot be removed. It aims to see if the drug can shrink tumors and help patients live longer.
Zhengzhou, HenanAges 18–75 - NCT07553572Recruiting
Smartphone app to track cancer symptoms during treatment
This study tests a smartphone application designed to help you monitor and manage side effects and symptoms while you're receiving chemotherapy or other systemic treatment for breast cancer, colorectal cancer, or lymphoma. The app may help your doctors catch problems early and support you throughout your treatment.
Boston, MassachusettsAges 18 years+ - NCT06413212Recruiting
Personalized drug test for advanced cancer with fluid buildup
This trial uses a special test on your cancer cells to find which chemotherapy might work best for you. The aim is to treat advanced cancer that has caused fluid buildup in the chest or abdomen.
Wuhan, HubeiAges 18 years+ - NCT06435351RecruitingEarly Phase 1
Personalized vaccine for high-risk triple-negative breast cancer
This trial tests a personalized vaccine made from your own immune cells (dendritic cells) to help prevent your high-risk triple-negative breast cancer from coming back. It is for people who had significant tumor left after standard chemotherapy and surgery.
Tampa, FloridaAges 18 years+ - NCT06172478RecruitingPhase 2
HER3-DXd for advanced solid tumors after prior treatment
This trial tests a new targeted drug called HER3-DXd for people with several types of advanced solid tumors that have stopped responding to standard treatments. The drug is an antibody-drug conjugate, designed to deliver chemotherapy directly to cancer cells that have a protein called HER3 on their surface.
Duarte, CaliforniaAges 18 years+ - NCT04861077RecruitingEarly Phase 1
PET/MRI monitoring for PD-L1–positive triple-negative breast cancer
This early-phase study uses advanced PET/MRI scans to monitor how immunotherapy treatment works in people with triple-negative breast cancer that is PD-L1 positive. It may help doctors better track tumor changes in the body over time.
Birmingham, AlabamaAges 18–75 - NCT04657068RecruitingPhase 1/Phase 2
Study of ART0380 for advanced solid tumors
This study tests a new drug called ART0380 for people with advanced solid tumors that have not responded to standard treatments. It may be especially helpful for those with certain DNA repair gene changes (like ATM or BRCA). The drug will be given alone or with chemotherapy (gemcitabine or irinotecan) depending on the part of the trial.
Birmingham, AlabamaAges 18 years+ - NCT04468061RecruitingPhase 2
Study chemo drug plus immunotherapy for metastatic triple-negative breast cancer
This trial tests sacituzumab govitecan (an antibody-drug medicine) with or without pembrolizumab (an immune-system therapy) in people with metastatic triple-negative breast cancer. It may help by shrinking tumors and improving immune control, especially for patients with specific tumor marker results.
Stamford, ConnecticutAges 18 years+ - NCT06111274RecruitingPhase 2
ABSK021 for untreated advanced pancreatic cancer
This trial tests a new drug called ABSK021 for people with advanced pancreatic cancer who have not received any prior treatment. It aims to see if the drug can shrink tumors or slow the cancer's growth.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07558733RecruitingPhase 1/Phase 2
New drug combinations for advanced hormone-receptor positive breast cancer
This trial tests two new drugs (sapanisertib and serabelisib) alone or together to treat advanced breast cancer that is hormone-receptor positive. These drugs target specific pathways that help cancer grow, and the trial will see if they work better than standard treatments.
Los Angeles, CaliforniaAges 18 years+
Hear when a new Advanced Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced breast cancer?
- Yes. Clin2 currently lists 937 recruiting advanced breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- Breast Cancer (Triple Negative Breast Cancer (TNBC))
- Locally Advanced Breast Cancer
- Locally Advanced or Metastatic Breast Cancer
- Advanced HR+/HER2- Breast Cancer
- Advanced Triple Negative Breast Cancer
- HER2-positive Advanced Breast Cancer
- Advanced/Metastatic Breast Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.